Vizgen Revenue and Competitors

Vizgen is the life sciences company developing the next generation of Spatially Resolved Transcriptomics. The Company's proprietary MERFISH (multiplexed error-robust fluorescence in situ hybridization) technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology enables a wide range of tissue-scale basic research and translational medicine and is instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. MERFISH is used as a tool for several Human Cell Atlas projects and was named a “Technology to Watch in 2018” by Nature. Tools employing MERFISH help to advance data-driven drug discovery and development and enable new insights for clinical pathology and diagnostics. “Vizgen's MERFISH technology undoubtedly will emerge as the next-gen platform for high-resolution spatial biology,” said Dr. David R. Walt, Co-founder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School; Professor of Pathology, Brigham and Women's Hospital; Core Faculty, Wyss Institute for Bioinspired Engineering, Harvard University; HHMI Professor. “It enables comprehensive transcriptomics combined with proteomics and has both whole tissue and subcellular resolution. It checks all the boxes.”